AACR 2026: Revolution Medicines' KRAS Inhibitor Shows Strong Trial Data
At the American Association for Cancer Research annual meeting in San Diego, Revolution Medicines presented further positive data for its KRAS-targeting cancer drug. The results add to growing momentum around KRAS inhibition as a treatment approach, with STAT News reporting that KRAS therapies are a dominant theme at this year's conference.
Advertisement: Article Inline